XML 31 R22.htm IDEA: XBRL DOCUMENT
v3.23.2

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2023
Novartis Institutes for BioMedical Research, Inc. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement were as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Revenue related to Novartis agreement: |  |  |  |  |  |  |
Recognition of upfront license fee | $ | 1,872 |  |  | $ | 8,622 |  |  | $ | 9,568 |  |  | $ | 15,640 |
Research services | 554 |  |  | 2,306 |  |  | 2,613 |  |  | 4,183 |
Total | $ | 2,426 |  |  | $ | 10,928 |  |  | $ | 12,181 |  |  | $ | 19,823 |
Biogen MA, Inc. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement were as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Revenue related to Biogen agreement: |  |  |  |  |  |  |
Recognition of license and other fixed consideration | $ | 1,535 |  |  | $ | 7,306 |  |  | $ | 132,165 |  |  | $ | 14,612 |
Cost-sharing payments for research services, net variable consideration | 669 |  |  | 2,746 |  |  | 2,341 |  |  | 6,633 |
Total | $ | 2,204 |  |  | $ | 10,052 |  |  | $ | 134,506 |  |  | $ | 21,245 |
Kite Pharma, Inc. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement were as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Revenue related to Kite agreement: |  |  |  |  |  |  |
Recognition of license fee fixed consideration | $ | 1,110 |  |  | $ | 6,227 |  |  | $ | 12,550 |  |  | $ | 12,386 |
Research services variable consideration | 121 |  |  | 107 |  |  | 989 |  |  | 256 |
Total | $ | 1,231 |  |  | $ | 6,334 |  |  | $ | 13,539 |  |  | $ | 12,642 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |